<DOC>
	<DOCNO>NCT02323971</DOCNO>
	<brief_summary>Dual antiplatelet therapy consist aspirin clopidogrel cornerstone treatment prevention thrombotic event patient coronary artery disease ( CAD ) , show reduction adverse event .</brief_summary>
	<brief_title>Impact Renal Function Ticagrelor-Induced Antiplatelet Effects Coronary Artery Disease Patients</brief_title>
	<detailed_description>Dual antiplatelet therapy consist aspirin clopidogrel cornerstone treatment prevention thrombotic event patient coronary artery disease ( CAD ) , show reduction adverse event . However , considerable number patient continue recurrent ischemic event despite regimen . In fact , last year several clinical factor associate impaired clopidogrel-induced effect . Moreover , clinical factor strongly relate presence high on-treatment platelet reactivity ( HPR ) , also associate occurrence adverse thrombotic event , include stent thrombosis , despite correct treatment compliance . Diabetes mellitus , acute coronary syndrome , obesity chronic kidney disease ( CKD ) common example . This observation encourage search new potent antiplatelet therapy . A new P2Y12 receptor antagonist , ticagrelor , approve clinical use . Ticagrelor new non-thienopyridine , cyclopentyltriazolo-pyrimidine ( CPTP ) , direct act reversible P2Y12 antagonist . This compound favorable pharmacokinetic ( PK ) pharmacodynamics ( PD ) profile clopidogrel , translate well clinical outcome patient acute coronary syndrome ( ACS ) recent large , international clinical trial . Interestingly , ticagrelor show impressive clinical benefit patient CKD comparison patient without renal impairment . CKD highly associate increase risk atherothrombotic event , include stent thrombosis , patient CAD . PD study show patient impaired renal function characterize reduce clopidogrel-induced antiplatelet effect higher rate HPR compare patient preserve renal function .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Ticagrelor</mesh_term>
	<criteria>Patients present moderatehigh risk nonSTEACS define accord current guideline Patients receive load dose chronic treatment aspirin ( 100 mg per day ) per standard care Age 18 80 year old BMI 18 35 kg/m2 Provide write informed consent prior study specific procedure History hemorrhagic stroke intracranial bleeding Known allergy aspirin , ticagrelor , clopidogrel On treatment oral anticoagulation ( Coumarin derivate , dabigatran , rivaroxaban , apixaban ) Hemoglobin &lt; 10 gm/dL Platelet count &lt; 80x106/mL Blood dyscrasia , active bleeding hemodynamic instability . Patients hemodialysis peritoneal dialysis , change estimate glomerular filtration rate ( eGFR ) great 15 mL/min within 90 day prior enrollment , estimate glomerular filtration rate ( eGFR ) low 15 mL/min/1.73m2 Patients know infectious disease neoplasia Baseline ALT &gt; 2.5 time upper limit normal Patients sick sinus syndrome ( SSS ) high degree AV block without pacemaker protection Drugs interfere 2C19 metabolism ( avoid interaction clopidogrel ) : fluconazole ( Diflucan ) , ketoconazole ( Nizoral ) , voriconazole ( VFEND ) , etravirine ( Intelence ) , felbamate ( Felbatol ) , fluoxetine ( Prozac , Serafem , Symbyax ) , fluvoxamine ( Luvox ) , ticlopidine ( Ticlid ) . Since omeprazole use protonpump inhibitor clinical environment , keep prescription rate group avoid difference result describe interaction Drugs interfere CYP3A4 metabolism ( avoid interaction Ticagrelor ) : Ketoconazole , itraconazole , voriconazole , clarithromycin , nefazodone , ritonavir saquinavir , nelfinavir , indinavir , atazanavir , telithromizycin Pregnant female</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2014</verification_date>
</DOC>